In a Phase 3 Trial, NovoEight® Provided Long-term Efficacy and Safety in the Prophylaxis and Treatment of Bleeds in People with Haemophilia A
Toronto (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress, Novo Nordisk announced the latest interim data from the guardian(TM)2 extension ...